ArticleAnimal models and experimental medicine2026
Establishment of a novel cynomolgus monkey model of hyperuricemia.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundChronic hyperuricemia is associated with complications such as gout and uric acid nephropathy, but uric acid also exhibits biological activities (e.g., antioxidant effects, potential neuroprotective properties against neurodegenerative diseases). Nonhuman primates are ideal models for studying neurodegenerative diseases; however, existing nonhuman primate hyperuricemia models cannot sustain long-term elevated serum uric acid levels, nor recapitulate the impaired uric acid excretion observed in clinical hyperuricemic patients.
methodsFirst, we detected uricase expression in cynomolgus monkeys and compared it with that in mice. Then, we established a cynomolgus monkey hyperuricemia model by administering a mixture of potassium oxonate, hydrochlorothiazide, and adenine via fruits and vegetables. We further analyzed the regulatory effects of this model on uric acid metabolism (synthesis, degradation, and excretion) and the expression of uric acid transporter genes in the intestine and kidney.
resultsCynomolgus monkeys express functional uricase, but at a lower level than mice. The established model maintained stable, long-term hyperuricemia by three mechanisms: increasing intestinal and renal uric acid excretion load, inhibiting hepatic uric acid degradation, and promoting uric acid synthesis. Additionally, the model downregulated the expression of intestinal/renal uric acid-secreting transporter genes, while upregulating uric acid-reabsorbing transporter genes.
conclusionsThis novel cynomolgus monkey hyperuricemia model provides a new tool for investigating the association between hyperuricemia and neurodegenerative diseases, and will help clarify the mechanism by which serum uric acid influences cognitive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.